Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Ben Z. Stanger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0410-4037; OpenAlex author ID A5057187872; NIH RePORTER profile ID 1865917. Sources: funder_awards.

Their work

Papers
52 (first author 3, last author 11)
Trials
0
Grants
6
Labs led
1
Collaborators
238
Papers, trials and grants by year

2007: 1 grant · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers, 1 grant · 2017: 3 papers · 2018: 1 paper · 2019: 3 papers · 2020: 5 papers · 2021: 2 papers · 2022: 4 papers, 1 grant · 2023: 3 papers · 2024: 10 papers · 2025: 6 papers, 1 grant · 2026: 6 papers, 2 grants

Papers 50 of 52

  1. DNA methylation-based classification uncovers acinar and ductal origins for KPC-derived PDAC cell lines. Co-author DOI 10.1016/j.canlet.2026.218666↗
  2. The HIF-2 transcription factor mediates resistance to ferroptosis in pancreatic cancer. Co-author DOI 10.1016/j.molcel.2026.03.007↗
  3. Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Co-author DOI 10.1038/s41598-026-35423-7↗
  4. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Last author DOI 10.1126/science.aec7929↗
  5. Aberrant O-glycosylation Induces IL-34-Mediated Immune Remodeling and Promotes Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-25-4782↗
  6. Tie2 inhibition disrupts TMEM doorway function and reduces dissemination in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-026-03730-6↗
  7. Mitochondrial Ca2+ controls pancreatic cancer growth and metastasis by regulating epithelial cell plasticity. Co-author DOI 10.1016/j.celrep.2025.115627↗
  8. A nuclear branched-chain amino acid catabolism pathway controls histone propionylation in pancreatic cancer Co-author DOI 10.1101/2025.04.23.650241↗
  9. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  10. Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy. Co-author DOI 10.1158/1078-0432.ccr-24-4049↗
  11. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2159-8290.cd-24-1475↗
  12. Pancreatic ductal adenocarcinoma: the Everest of cancer biology. First author DOI 10.1172/jci191936↗
  13. Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Co-author DOI 10.1016/j.celrep.2024.114972↗
  14. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice. Co-author DOI 10.1038/s41467-024-50441-7↗
  15. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  16. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  17. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  18. A Histone Methylation-MAPK Signaling Axis Drives Durable Epithelial-Mesenchymal Transition in Hypoxic Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2945↗
  19. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-23-2352↗
  20. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-24-1926↗
  21. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-23-0519↗
  22. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  23. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Co-author DOI 10.1158/1541-7786.mcr-22-0602↗
  24. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
  25. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-22-1066↗
  26. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  27. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.abn0704↗
  28. Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-22-0431↗
  29. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Last author DOI 10.1158/2159-8290.cd-20-1826↗
  30. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-20-0519↗
  31. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  32. Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jcmgh.2020.04.016↗
  33. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Co-author DOI 10.1016/j.xcrm.2020.100131↗
  34. Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer Co-author DOI 10.1101/2020.05.15.098368↗
  35. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adeno… Co-author DOI 10.1158/1078-0432.ccr-19-3313↗
  36. Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer. Last author DOI 10.1158/2326-6066.cir-19-0661↗
  37. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Co-author DOI 10.1053/j.gastro.2019.05.004↗
  38. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. Co-author DOI 10.1126/sciadv.aav6789↗
  39. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cance… Co-author DOI 10.1155/2019/6402925↗
  40. miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3703↗
  41. Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes. Co-author DOI 10.1021/acsnano.7b05503↗
  42. Upholding a role for EMT in pancreatic cancer metastasis. Last author DOI 10.1038/nature22963↗
  43. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-2128↗
  44. Orthotopic Injection of Pancreatic Cancer Cells. Last author DOI 10.1101/pdb.prot078360↗
  45. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. Co-author DOI 10.1172/jci.insight.88328↗
  46. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  47. Pancreatic Cancer Metastases Harbor Evidence of Polyclonality. First author DOI 10.1158/2159-8290.cd-15-0120↗
  48. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. Co-author DOI 10.1371/journal.pone.0118933↗
  49. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ccr.2014.04.021↗
  50. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Co-author DOI 10.1016/j.celrep.2013.05.036↗

Grants 6

  1. Stromal and vascular inputs into pancreatic cancer tumor neighborhoods R01CA276512↗
  2. Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategies R01CA303474↗
  3. Defining metabolic adaptations within the PDAC "arid" tumor microenvironment R01CA252225↗
  4. Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer R01CA229803↗
  5. Immunobiology and immunotherapy of pancreatic cancer R01CA169123↗
  6. Investigation of the Pancreatic ‘Ductome’ AWARD pancan:2007-ben-stanger-md-phd-investigation-of-the-pancreatic-ductome

Closest collaborators

The 25 strongest of 238 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert H. Vonderheide · 8 shared papers, 3 shared grants, 2012–2026 · strength 3.31
  2. Chi Van Dang · 3 shared papers, 1 shared grant, 2022–2026 · strength 1.62
  3. M. Celeste Simon · 2 shared papers, 1 shared grant, 2024–2026 · strength 1.61
  4. Minh T. Than · 3 shared papers, 2024–2026 · strength 1.08
  5. Jinyang Li · 9 shared papers, 2019–2023 · strength 1.00
  6. Jason Robert Pitarresi · 7 shared papers, 2020–2025 · strength 0.99
  7. Samantha B. Kemp · 5 shared papers, 2023–2025 · strength 0.93
  8. Robert J. Norgard · 7 shared papers, 2019–2022 · strength 0.78
  9. Kim A. Reiss · 3 shared papers, 2024–2026 · strength 0.75
  10. Anirban Maitra · 3 shared papers, 2021–2024 · strength 0.59
  11. Mark H. O’Hara · 4 shared papers, 2017–2024 · strength 0.59
  12. Salina Yuan · 4 shared papers, 2020–2023 · strength 0.50
  13. Andrew J. Aguirre · 2 shared papers, 2024 · strength 0.49
  14. Gregory Lawrence Beatty · 3 shared papers, 2012–2026 · strength 0.48
  15. Erica L. Carpenter · 5 shared papers, 2017–2024 · strength 0.46
  16. Margo Orlen · 2 shared papers, 2025 · strength 0.44
  17. Alexander Muir · 2 shared papers, 2022–2026 · strength 0.41
  18. Maimon E. Hubbi · 2 shared papers, 2022–2026 · strength 0.41
  19. John Christopher McAuliffe · 2 shared papers, 2022–2026 · strength 0.34
  20. Edna Cukierman · 2 shared papers, 2023–2024 · strength 0.32
  21. Benjamin Kahn · 2 shared papers, 2023–2024 · strength 0.32
  22. Nicole M. Aiello · 5 shared papers, 2015–2017 · strength 0.31
  23. Yanqing Jiang · 2 shared papers, 2021–2024 · strength 0.29
  24. Erin Elizabeth Hollander · 1 shared paper, 2026 · strength 0.29
  25. Nina G. Steele · 2 shared papers, 2022–2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.